4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Zacks Investment Research9/21/2026Positive
ABOS
Acumen Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$161.99M
P/E Ratio
—
EPS
$-1.64
Beta
0.38
52W High
$3.60
52W Low
$1.45
50-Day MA
$2.61
200-Day MA
$2.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.
Fundamentals
| Revenue (TTM) | 329,000 |
| Gross Profit (TTM) | $-86.79M |
| EBITDA | $-105.37M |
| Operating Margin | 0.00% |
| Return on Equity | -120.50% |
| Return on Assets | -45.80% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.79 |
| Price-to-Book | 2.91 |
| Price-to-Sales (TTM) | 538.78 |
| EV/Revenue | 24.48 |
| EV/EBITDA | -0.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $72.32M |
| Float | $37.05M |
| % Insiders | 6.79% |
| % Institutions | 66.60% |
Historical Volatility
HV 10-Day
90.59%
HV 20-Day
81.33%
HV 30-Day
82.79%
HV 60-Day
73.53%
HV Rank
57.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.60 target)
6
BuyLatest News
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
Seeking Alpha9/16/2026Neutral
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.
GlobeNewsWire9/10/2026Neutral
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha9/10/2026Neutral
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.
GlobeNewsWire9/2/2026Neutral
Acumen Pharmaceuticals Q2 Earnings Call Highlights
Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.
MarketBeat8/12/2026Neutral
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.
GlobeNewsWire8/12/2026Neutral
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Zacks Investment Research7/31/2026Positive
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research7/15/2026Positive
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Zacks Investment Research7/15/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABOS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026